Clinical Trials Directory

Trials / Completed

CompletedNCT02901600

Expression of DMBT1 in Colorectal Cancer Patients

Modification of the Expression and the Localization of DMBT1 (Deleted in Malignant Brain Tumor 1) in Colorectal Cancer

Status
Completed
Phase
Study type
Observational
Enrollment
145 (actual)
Sponsor
Lille Catholic University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Although colorectal cancer is a preventable and curable disease if early stage tumors are removed, it is still the fourth cause of cancer worldwide and the second leading cause of death in many industrialized countries. The 5-year survival is about 55% often due to a late detection. Then, the identification of sensitive and specific molecular markers is therefore a major challenge for early diagnosis and prognosis of this disease. Preliminary work have reported variations in the expression of DMBT1 (deleted in malignant brain tumor 1), a glycoprotein co-secreted with mucins in the light of the glands, during several stages of colon carcinogenesis. The goal of this study is to study by mass spectrometry (MS), alterations in the repertoire of glycosylation of mucins from colorectal tumors of various stages, grades, and recurrence status.

Conditions

Interventions

TypeNameDescription
OTHERDetection of the expression of DMTB1 by immunohistochemistry

Timeline

Start date
2013-06-01
Primary completion
2015-06-01
Completion
2015-11-01
First posted
2016-09-15
Last updated
2016-09-15

Source: ClinicalTrials.gov record NCT02901600. Inclusion in this directory is not an endorsement.